AOM Infusion Selected as a Limited Distribution Specialty Pharmacy for QIVIGY®, A New Immune Globulin Therapy

AOM Infusion ("AOM"), a leading specialty infusion pharmacy and provider, today announced it has joined Kedrion Biopharma’s limited distribution network for QIVIGY®, a new 10% immune globulin (Ig) ...

"I was fighting to survive": Patients still struggle with preauthorization despite promise of reform

Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.
KFF Health News on MSN

Families Scramble To Pay Five-Figure Bills as Clock Ticks on Promised Preauthorization Reforms

Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, which often requires patients or their doctors to seek preapproval from insurers ...

A vitamin cocktail, straight to the vein. IV drip bars boom in Boston, but are they worth the hype?

Myers’ Cocktail: Perhaps the best-known IV blend, this mixture of vitamin C, B vitamins, magnesium, and calcium dates back to ...
Sierra Sun Times

KFF Health News: Families Scramble To Pay Five-Figure Bills as Clock Ticks on Promised Preauthorization Reforms for Medical Care

Kelly for KFF Health News) March 14, 2026 - By Lauren Sausser - Sheldon Ekirch is used to being disappointed by her health insurance company. That’s why Ekirch, 31, of Henrico, Virginia, was stunned ...
Miami Community Newspapers

The Rise of IV Hydration Clinics in Florida: What Consumers and Providers Need to Know

IV hydration lounges and mobile “drip therapy” services have rapidly expanded across Florida, promising quick recovery from dehydration, fatigue, and illness through vitamin and fluid infusions ...
Scientific American

A hidden kidney threat—and new treatments that make detecting it critical

IgA nephropathy, an immune assault on the kidneys, is often missed. New treatments mean that spotting it sooner might save lives ...

Twice‑yearly injectable HIV regimen treatment demonstrates strong efficacy and safety in Phase 2 trial

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...
CURE

New Approach May Reduce Recurrence in Muscle-Invasive Bladder Cancer

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...